Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis
暂无分享,去创建一个
H. Lo | G. Lesser | D. Soto-Pantoja | Dawen Zhao | B. Westwood | L. Metheny-Barlow | Adam S. Wilson | Jessica D. Mackert | Elizabeth R. Stirling | K. Cook
[1] Jingping Yuan,et al. MiR-133a/CD47 axis is a novel prognostic biomarker to promote triple negative breast cancer progression. , 2023, Pathology, research and practice.
[2] S. Shigdar,et al. Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis , 2022, Cancers.
[3] M. Maio,et al. Immunotherapy for brain metastases and primary brain tumors. , 2022, European journal of cancer.
[4] L. Miller,et al. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response , 2022, Journal for immunotherapy of cancer.
[5] Katherine L. Cook,et al. Discrete Correlation Summation Clustering Reveals Differential Regulation of Liver Metabolism by Thrombospondin-1 in Low-Fat and High-Fat Diet-Fed Mice , 2022, Metabolites.
[6] Hongyue Wang,et al. Lysyl hydroxylase 1 (LH1) deficiency promotes angiotensin II (Ang II)-induced dissecting abdominal aortic aneurysm , 2021, Theranostics.
[7] Jifeng Feng,et al. Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets , 2021, OncoTargets and therapy.
[8] Peter B. McGarvey,et al. UniProt: the universal protein knowledgebase in 2021 , 2020, Nucleic Acids Res..
[9] M. Moses,et al. Metalloproteinases and their roles in human cancer , 2020, Anatomical record.
[10] Runan Yao,et al. ShinyGO: a graphical gene-set enrichment tool for animals and plants , 2019, Bioinform..
[11] L. Jia,et al. Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy , 2019, OncoTargets and therapy.
[12] N. Jahchan,et al. Tuning the Tumor Myeloid Microenvironment to Fight Cancer , 2019, Front. Immunol..
[13] I. Weissman,et al. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma , 2019, Proceedings of the National Academy of Sciences.
[14] I. Weissman,et al. CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.
[15] Amy Y. Chen,et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile , 2018, PloS one.
[16] M. Ferrer,et al. Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy , 2018, Breast Cancer Research and Treatment.
[17] T. Minko,et al. Metastatic and triple-negative breast cancer: challenges and treatment options , 2018, Drug Delivery and Translational Research.
[18] C. Anders,et al. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. , 2018, Annals of translational medicine.
[19] N. Howlader,et al. Differences in Breast Cancer Survival by Molecular Subtypes in the United States , 2018, Cancer Epidemiology, Biomarkers & Prevention.
[20] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[21] A. Elkahloun,et al. A function-blocking CD47 antibody modulates extracellular vesicle-mediated intercellular signaling between breast carcinoma cells and endothelial cells , 2018, Journal of Cell Communication and Signaling.
[22] Zihai Li,et al. Is CD47 an innate immune checkpoint for tumor evasion? , 2017, Journal of Hematology & Oncology.
[23] C. Schneider,et al. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide , 2016, Clinical & Experimental Metastasis.
[24] I. Weissman,et al. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo , 2016, PloS one.
[25] yang-xin fu,et al. CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.
[26] P. Sharma,et al. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.
[27] J. Berzofsky,et al. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. , 2014, Cancer research.
[28] M. Merino,et al. Abstract 2434: Therapeutic targeting of CD47 regulates cell bioenergetics and autophagy to reduce breast tumor growth and protect against anthracycline-mediated cardiac toxicity , 2014 .
[29] D. Wink,et al. Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling , 2009, Science Translational Medicine.
[30] T. Matozaki,et al. CD47 regulation of epithelial cell spreading and migration, and its signal transduction , 2006, Cancer science.
[31] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[32] D. Kell,et al. The Kyoto Encyclopedia of Genes and Genomes—KEGG , 2000, Yeast.
[33] S. Cheshier,et al. Microglia in the Brain Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.